Advancing Immunology for Cutting-Edge Patient Solutions

We are committed to pushing the boundaries of immunology, leveraging cutting-edge research to create innovative therapies that enhance patient care, combat diseases, and improve lives worldwide.

Read More

Theravac Bio focuses on immune intervention strategies with two key programs: Therapeutic Tumor Vaccine and Reconstruction of Immune Homeostasis. The therapeutic tumor vaccine aims to enhance tumor immunogenicity and activate both T-cell and humoral immune responses. The lead product, a lung cancer vaccine targeting Non-Small Cell Lung Cancer (NSCLC), has shown strong preclinical efficacy and is currently in a Phase I clinical trial.

The Immune Homeostasis Program leverages the unique properties of invariant Natural Killer T (iNKT) cells to restore immune balance, regulate inflammation and metabolism, and improve sub-health conditions. Initial studies demonstrate that iNKT cell infusion can reconstruct immune homeostasis and support metabolic health. This program is advancing through Phase I/II clinical trials.

Our Company Background

Theravacbio is a clinical-stage biotech company

dedicated to the innovation and development of next-generation immunotherapies.

TheravacBio's immunotherapies

Our immune intervention strategies fall into two categories:
First, for subhealthy populations, we employ iNKT cell technology, which combines features of both innate and adaptive immunity, to restore immune homeostasis. This approach helps control inflammation, combat infections, resist tumors, regulate metabolism, and promote overall health.

Second, for cancer patients, we utilize the tumor therapeutic vaccines to overcome the bottlenecks of tumor immunosuppressive microenvironments, tumor heterogeneity, and low immunogenicity. This strategy aims to awaken and enhance tumor-specific protective immune responses, thereby inhibiting tumor growth.

Our Breakthrough Innovations

Discover how TheravacBio is pioneering immune-based therapies through advanced technologies and personalized solutions.

Therapeutic Tumor Vaccines

The introduction of immune checkpoint inhibitors (ICIs) has confirmed T-cell-mediated tumor control, highlighting the clinical value of T-cell-based immunotherapy. Key studies demonstrate that edongenous T cells can recognize mutated cancer-specific epitopes presented by major histocompatibility complexes , which mediate effective anti-tumor responses. However, since tumor antigens derive from normal cells, they possess low immunogenicity due to the immune system's tolearance to "self".This presents a challenge in activating robust immune responses through traditional methods, thereby hindering the development of therapeutic tumor vaccines.
Based on our innovative CYplus adjuvant technology, we developed a therapeutic lung cancer vaccine using a recombinant viral vector. This vaccine incorporates an advanced adjuvant system that effectively activates the immune response, addressing the challenges posed by the weak immunogenicity of tumor antigens and the tumor's immunosuppressive microenvironment. It demonstrated robust broad-spectrum anti-tumor activity through the co-expression of multiple tumor antigens, thereby targeting tumor heterogeneity effectively.

read more

Reconstruction of Immune homeostasis

Type I invariant natural killer T (iNKT) cells possess characteristics of both innate immunity (NK cells) and adaptive immunity (T cells). Upon activation, iNKT cells can specifically eliminate tumor and infected cells, removing those that pose a risk to the body’s health. They secrete various cytokines to modulate immune responses, maintaining a balanced state—preventing weakened immunity that could lead to cancer or infections while avoiding excessive immune responses that may cause allergies or autoimmune diseases. iNKT cells play a crucial role in anti-tumor defense, infection control, and immune regulation, surpassing the capabilities of NK cells.

read more

We aim to harness the immune system's full potential by combining next-gen immunomodulatory strategies with diverse biological targets to treat cancer, infectious, and other high-burden diseases.

One Mission.
Endless Innovation.
A New Era Against Cancer.
Powered by viral vector expertise,
driven to save lives.

Call

Call us
03 8564 8561

Email

Email us
contact@
theravacbio.com.au

Address

Address
Suite 178, 793 Burke Road,
Camberwell, Victoria 3124

© 2024 Theravacbio Clone. All rights reserved.